Active Substance Master File (ASMF)

Procedures,ASMF,holder,Active substances,letter,product,Active substance master file,letter of access,substance master file procedure,medicinal product,requirements,applicants,time,European,submission letter,format,form,application form,preparations,questions,cover letter,letter of access issued,relevant letter,electronic format,worksharing procedure,parent procedure,sharing procedure,drug product,request form,process,assessment process,technical requirements,authorisation.

Responsibilities with respect,type,materials,CEP for materials,materials of animal,CTS ASMF,Health Canada,herbal drug preparation,European Medicines Agency,closure,processing,clarification,manufacturing method,methods,North America,CEP in Modules,curriculum vitae,Restricted Part (RP,assessment repository,Additional guidance,chemical substance,national applications,human origin,transmissible spongiform encephalopathies,veterinary medicines,acknowledgement letter,process hold letter.

MF Authorized Third Party Authorization Letter,MF Letter of Deficiency,Sample – Letter,transfer of ownership letter,writing via cover letter,CEP attestation letter,non-eCTD format,non-eCTD or eCTD format,proper non-eCTD or eCTD format,correct format,incorrect format,proper format,”Non-eCTD Electronic-Only” Format,”””Non-eCTD Electronic-Only”” Format,Guidance Document”,alternative format(PDF format,applicable format,Centralized procedure,- Procedures,”2022.https://www.ema.europa.eu/en/about-us/about-website/glossary/name_az/C.

Decentralised procedure”,alternate procedure,Analytical Procedures,assessment procedures,centralised procedure,family of products,Blood Products,Certified Product,drug product intermediates,drug product manufacturer,product manufacturing,applications for products,”CanadaE-mail:bpsenquiries@hc-sc.gc.ca,Therapeutic Products”,Dosage forms,finished dosage form,”MF Application Fee Form,”,templaterequest form,administrative process,manufacturing process,registration process,submission process,filing requirements,formatting requirements,baseline requirement,request for authorisation,applications for marketing authorisation,Authorisation of medicines,authorisation routes,respect,clarity with respect,respect to quality information,communications with respect,authorized applicants,applicant access,clinical trial Applicants,Type IV MF,Type I MFs,Type V MFs,time of filing,prescribed time,additional time,raw materials,starting material,materials of animal origin,agents of animal spongiform,animal spongiform encephalopathies,complete ASMF,MF Holder,MF Holder Address,Health Canada’s,human health,preparation of cell banks,European Drug Master File (EDMF,Container closure systems,complete container closure system,- questions,CMDh-CMDv Questions,additional processing steps,administrative processing,responses to clarification requests,calendar day clarification request,analytical methods.